GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Beneish M-Score
中文

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Beneish M-Score

: -2.12 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.12 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sonoma Pharmaceuticals's Beneish M-Score or its related term are showing as below:

SNOA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.6   Med: -2.41   Max: 8.01
Current: -2.12

During the past 13 years, the highest Beneish M-Score of Sonoma Pharmaceuticals was 8.01. The lowest was -3.60. And the median was -2.41.


Sonoma Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Sonoma Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.37 -3.04 -2.55 -2.44 -1.56

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.15 -1.56 -2.44 -2.99 -2.12

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Beneish M-Score falls into.



Sonoma Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sonoma Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2771+0.528 * 0.8917+0.404 * 0.687+0.892 * 0.9804+0.115 * 0.8123
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7309+4.679 * 0.041251-0.327 * 0.7436
=-2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.88 Mil.
Revenue was 3.138 + 2.731 + 3.427 + 3.014 = $12.31 Mil.
Gross Profit was 1.46 + 0.99 + 1.204 + 0.864 = $4.52 Mil.
Total Current Assets was $12.50 Mil.
Total Assets was $14.62 Mil.
Property, Plant and Equipment(Net PPE) was $0.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.17 Mil.
Selling, General, & Admin. Expense(SGA) was $7.29 Mil.
Total Current Liabilities was $3.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.16 Mil.
Net Income was -0.866 + -1.484 + -1.418 + -1.308 = $-5.08 Mil.
Non Operating Income was -0.079 + -0.09 + -0.211 + -0.308 = $-0.69 Mil.
Cash Flow from Operations was -1.104 + -1.231 + -0.215 + -2.441 = $-4.99 Mil.
Total Receivables was $2.30 Mil.
Revenue was 2.944 + 3.331 + 3.983 + 2.298 = $12.56 Mil.
Gross Profit was 0.831 + 1.536 + 1.646 + 0.096 = $4.11 Mil.
Total Current Assets was $11.23 Mil.
Total Assets was $13.93 Mil.
Property, Plant and Equipment(Net PPE) was $0.79 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.14 Mil.
Selling, General, & Admin. Expense(SGA) was $10.18 Mil.
Total Current Liabilities was $3.93 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.876 / 12.31) / (2.297 / 12.556)
=0.233631 / 0.18294
=1.2771

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4.109 / 12.556) / (4.518 / 12.31)
=0.327254 / 0.367019
=0.8917

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12.502 + 0.738) / 14.618) / (1 - (11.232 + 0.785) / 13.928)
=0.094267 / 0.137206
=0.687

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.31 / 12.556
=0.9804

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.14 / (0.14 + 0.785)) / (0.169 / (0.169 + 0.738))
=0.151351 / 0.186329
=0.8123

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7.294 / 12.31) / (10.179 / 12.556)
=0.592526 / 0.810688
=0.7309

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.16 + 3.074) / 14.618) / ((0.21 + 3.934) / 13.928)
=0.221234 / 0.29753
=0.7436

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.076 - -0.688 - -4.991) / 14.618
=0.041251

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sonoma Pharmaceuticals has a M-score of -2.12 suggests that the company is unlikely to be a manipulator.


Sonoma Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Headlines

From GuruFocus